Learn Before
Discussion: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- No significant difference was found between the high and low dose groups response in specific antibody production
- positive T cell responses were measured in 90% and 88% of the high and low dose groups respectively
- Preexisting immunity and older age negatively impacted the responses to vaccination
- Most adverse reactions were mild to moderate and resolved in less than 2 days
- Most people reported worse adverse reactions in the high dose group than the low dose group
- The low dose group has a good safety profile and the results support its testing in a phase 3 clinical trial
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Methods: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Results: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Discussion: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial